Literature DB >> 1864013

Interleukin-2 receptor gene expression in kidney transplant recipients treated with cyclosporin A.

N Yoshimura1, T Oka, T Amagai, Y Horii, J Imanishi.   

Abstract

We examined the effects of cyclosporin A (CsA) administered in vivo on the capacity of peripheral blood mononuclear cells (PBMC) from kidney transplant recipients to express IL-2 receptor (IL-2R) gene at the level of mRNA after mitogen stimulation in vitro. There were no differences in the percentage of IL-2R+ cells among the groups of normal individuals, azathioprine-prednisolone treated, and CsA-prednisolone-treated recipients, using FITC-labelled monoclonal anti-IL-2R antibody (anti-alpha chain): 40.3 +/- 10.1% and 62.8 +/- 11.1% of normal PBMC (n = 18), 37.0 +/- 9.3% and 61.7 +/- 5.8% of PBMC from azathioprine-prednisolone-treated recipients (n = 20), and 37.7 +/- 9.6% and 60.7 +/- 12.7% of PBMC from CsA-prednisolone-treated recipients (n = 20) expressed IL-2R after 24 h and 48 h of phytohaemagglutinin stimulation, respectively. However, in a study of Northern blotting using cDNA for IL-2R (anti-alpha chain specific), both the 3500 and 1400 bp families of IL-2R mRNA were remarkably decreased in PBMC from CsA-prednisolone-treated recipients compared with azathioprine-prednisolone-treated recipients and normal individuals. These studies demonstrated that CsA could inhibit IL-2R gene expression at the level of mRNA at physiological concentration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864013      PMCID: PMC1535752          DOI: 10.1111/j.1365-2249.1991.tb05727.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Corticosteroids and bioavailability.

Authors:  S S Stubbs
Journal:  Transplant Proc       Date:  1975-03       Impact factor: 1.066

2.  Effect of cyclosporin A on the early activation of human T helper lymphocytes: inhibition of RNA-synthesis and modification of the expression of activation antigens.

Authors:  F Bettens; C Walker; G D Bonnard; A L de Weck
Journal:  Immunobiology       Date:  1985-12       Impact factor: 3.144

3.  Expression of interleukin 2, interferon-gamma, and the IL 2 receptor by human peripheral blood lymphocytes.

Authors:  K Grabstein; S Dower; S Gillis; D Urdal; A Larsen
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

4.  Combination therapy of cyclosporine with steroid inhibits gamma-interferon and interleukin-1 gene expression at the level of mRNA synthesis in vivo.

Authors:  N Yoshimura; T Oka; M Kita; H Teraoka; Y Hirai
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

5.  Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression.

Authors:  J C Reed; A H Abidi; J D Alpers; R G Hoover; R J Robb; P C Nowell
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

6.  Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance?

Authors:  M Abbud-Filho; J W Kupiec-Weglinski; J L Araujo; C D Heidecke; N L Tilney; T B Strom
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

7.  The inhibition of interleukin 2 (IL-2) gene expression at the level of messenger RNA by in vivo cyclosporine treatment in kidney transplant recipients.

Authors:  N Yoshimura; T Oka; S C Clark; B D Kahan
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

8.  Molecular cloning of cDNA encoding human interleukin-2 receptor.

Authors:  T Nikaido; A Shimizu; N Ishida; H Sabe; K Teshigawara; M Maeda; T Uchiyama; J Yodoi; T Honjo
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

9.  Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.

Authors:  K Teshigawara; H M Wang; K Kato; K A Smith
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

10.  Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  A Granelli-Piperno; L Andrus; R M Steinman
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.